On the contrary, Lupinacci and Delyon et al. reported that mammalian target of rapamycin inhibitors, such as sirolimus, could treat KS in renal transplant recipients based on the capacity of sirolimus to abrogate VEGF-induced tumour proliferation (4, 23). Here, MTOR is linked to Kaposi's sarcoma.